A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2024 Mar 28

PMID 38541083

Authors

En-Hao Hu

Ming-Lung Tsai

Yuan Lin

Tien-Shin Chou

Tien-Hsing Chen

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce glucose levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the mechanisms and potential benefits of several GLP-1 RAs. In particular, this meta-analysis focuses on the safety and associations with weight loss, glucose reduction, cardiovascular outcomes, heart failure, and renal outcomes of GLP-1 RAs to determine their benefits for patients with different conditions. In terms of glycemic control and weight loss, semaglutide was statistically superior to other GLP-1 RAs. In terms of cardiovascular outcomes, 14 mg of semaglutide taken orally once daily and 1.8 mg of liraglutide injected once daily reduced the incidence of cardiovascular death, whereas other GLP-1 RAs did not provide similar benefits. Moreover, semaglutide was associated with superior outcomes for heart failure and cardiovascular death in non-diabetic obesity patients, whereas liraglutide worsened heart failure outcomes in diabetic patients with a reduced ejection fraction. Additionally, semaglutide, dulaglutide, and liraglutide were beneficial in terms of composite renal outcomes: These GLP-1 RAs were significantly associated with less new or persistent macroalbuminuria, but not with improved eGFR deterioration or reduced requirement for renal replacement therapy. However, GLP-1 RAs may benefit patients with type 2 diabetes mellitus or obesity.

Citing Articles

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.

Wang C, Wu Z, Zhou J, Cheng B, Huang Y J Cancer Res Clin Oncol. 2025; 151(3):103.

PMID: 40055197 PMC: 11889073. DOI: 10.1007/s00432-025-06154-5.

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.

He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.

PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

King A, Tan X, Dhopeshwarkar N, Bohn R, Dea K, Leonard C Am J Prev Cardiol. 2025; 21:100922.

PMID: 39896054 PMC: 11786665. DOI: 10.1016/j.ajpc.2024.100922.

Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients.

Levy S, Attia A, Elshazli R, Abdelmaksoud A, Tatum D, Aiash H Cancers (Basel). 2025; 17(1.

PMID: 39796706 PMC: 11720624. DOI: 10.3390/cancers17010078.

Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.

Salmen T, Potcovaru C, Bica I, Giglio R, Patti A, Stoica R Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458963 PMC: 11510241. DOI: 10.3390/ph17101322.

References

Trujillo J, Nuffer W . GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014; 34(11):1174-86. DOI: 10.1002/phar.1507. View

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Goud A, Zhong J, Peters M, Brook R, Rajagopalan S . GLP-1 Agonists and Blood Pressure: A Review of the Evidence. Curr Hypertens Rep. 2016; 18(2):16. DOI: 10.1007/s11906-015-0621-6. View

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

Pratley R, Nauck M, Barnett A, Feinglos M, Ovalle F, Harman-Boehm I . Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014; 2(4):289-297. DOI: 10.1016/S2213-8587(13)70214-6. View

Sorli C, Harashima S, Tsoukas G, Unger J, Karsbol J, Hansen T . Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5(4):251-260. DOI: 10.1016/S2213-8587(17)30013-X. View

Capehorn M, Catarig A, Furberg J, Janez A, Price H, Tadayon S . Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2019; 46(2):100-109. DOI: 10.1016/j.diabet.2019.101117. View

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Davidson M, Bate G, Kirkpatrick P . Exenatide. Nat Rev Drug Discov. 2005; 4(9):713-4. DOI: 10.1038/nrd1828. View

10.

Dyachok O, Gylfe E . Ca(2+)-induced Ca(2+) release via inositol 1,4,5-trisphosphate receptors is amplified by protein kinase A and triggers exocytosis in pancreatic beta-cells. J Biol Chem. 2004; 279(44):45455-61. DOI: 10.1074/jbc.M407673200. View

11.

Anderson S, Beutel T, Trujillo J . Oral semaglutide in type 2 diabetes. J Diabetes Complications. 2020; 34(4):107520. DOI: 10.1016/j.jdiacomp.2019.107520. View

12.

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M . 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. View

13.

Smith N, Hackett T, Galli A, Flynn C . GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019; 128:94-105. PMC: 7081944. DOI: 10.1016/j.neuint.2019.04.010. View

14.

Glaser B, Cerasi E . Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab. 2001; 1(2):67-74. DOI: 10.1046/j.1463-1326.1999.00015.x. View

15.

McCarty D, Coleman M, Boland C . Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management. Ann Pharmacother. 2017; 51(5):401-409. DOI: 10.1177/1060028017689878. View

16.

Drucker D, Dritselis A, Kirkpatrick P . Liraglutide. Nat Rev Drug Discov. 2010; 9(4):267-8. DOI: 10.1038/nrd3148. View

17.

Husain M, Birkenfeld A, Donsmark M, Dungan K, Eliaschewitz F, Franco D . Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381(9):841-851. DOI: 10.1056/NEJMoa1901118. View

18.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

19.

Crajoinas R, Oricchio F, Pessoa T, Pacheco B, Lessa L, Malnic G . Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011; 301(2):F355-63. DOI: 10.1152/ajprenal.00729.2010. View

20.

Jorsal A, Kistorp C, Holmager P, Tougaard R, Nielsen R, Hanselmann A . Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2016; 19(1):69-77. DOI: 10.1002/ejhf.657. View